- Home
- OLED vs ROIV Comparison
OLED vs ROIV Comparison
Compare OLED & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OLED
- ROIV
- Stock Information
- Founded
- OLED 1985
- ROIV 2014
- Country
- OLED United States
- ROIV United Kingdom
- Employees
- OLED N/A
- ROIV N/A
- Industry
- OLED Semiconductors
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- OLED Technology
- ROIV Health Care
- Exchange
- OLED Nasdaq
- ROIV Nasdaq
- Market Cap
- OLED 7.2B
- ROIV 8.4B
- IPO Year
- OLED 1992
- ROIV N/A
- Fundamental
- Price
- OLED $154.53
- ROIV $10.76
- Analyst Decision
- OLED Strong Buy
- ROIV Buy
- Analyst Count
- OLED 7
- ROIV 4
- Target Price
- OLED $190.43
- ROIV $17.50
- AVG Volume (30 Days)
- OLED 718.9K
- ROIV 5.9M
- Earning Date
- OLED 05-01-2025
- ROIV 05-29-2025
- Dividend Yield
- OLED 1.17%
- ROIV N/A
- EPS Growth
- OLED 4.58
- ROIV N/A
- EPS
- OLED 4.81
- ROIV N/A
- Revenue
- OLED $648,702,000.00
- ROIV $122,585,000.00
- Revenue This Year
- OLED $5.35
- ROIV N/A
- Revenue Next Year
- OLED $13.88
- ROIV N/A
- P/E Ratio
- OLED $32.13
- ROIV N/A
- Revenue Growth
- OLED 6.13
- ROIV 140.04
- 52 Week Low
- OLED $103.70
- ROIV $8.73
- 52 Week High
- OLED $237.00
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- OLED 68.62
- ROIV 49.33
- Support Level
- OLED $139.13
- ROIV $10.58
- Resistance Level
- OLED $157.57
- ROIV $11.77
- Average True Range (ATR)
- OLED 5.69
- ROIV 0.34
- MACD
- OLED 3.48
- ROIV -0.05
- Stochastic Oscillator
- OLED 91.93
- ROIV 15.13
About OLED Universal Display Corporation
Universal Display Corp researches, develops, and manufactures organic light-emitting diode, or OLED, technologies for use in displays for mobile phones, tablets, televisions, wearables, personal computers, automotive interiors, and the solid-state lighting market. OLED technologies are an alternative to light-emitting diode, or LED, technologies, in the solid-state lighting market, and liquid crystal displays in the flat-panel-display market. A large majority of the firm's revenue is generated in South Korea, with the rest coming from Japan, China, the United States, and other countries across the world.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.